<DOC>
	<DOCNO>NCT01053000</DOCNO>
	<brief_summary>To determine compare safety efficacy broad area photodynamic therapy aminolevulinic acid ( ALA-PDT ) follow topical retinoid pre-treatment v ALA-PDT occlusion ( pretreatment ) subject dorsal hand/forearm actinic keratoses , incubation time 60 minute , use blue light .</brief_summary>
	<brief_title>Photodynamic Therapy With Levulan® +/- Topical Retinoid Pre-Treatment In The Treatment Of Actinic Keratoses</brief_title>
	<detailed_description>Subjects randomize RIGHT dorsal hand/forearm receive one follow two treatment subject 's LEFT dorsal hand/forearm receiving treatment ; Treatment 1 include pre-treatment dorsal hand/forearm Tazorac 0.1 % gel BID one week , follow ALA apply entire dorsal hand/forearm 60 minute prior BLUE light treatment 16 minute 40 second Treatment 2 ALA apply entire dorsal hand/forearm occlude 60 minute prior BLUE light treatment 16 minute 40 secondsNote : ALA apply individual dorsal hand/forearm actinic keratoses ( AK ) lesion follow broad area application entire dorsal hand/forearm surface . The treatment area side NOT pre-treated Tazorac occlude use plastic wrap 60 minute . The treatment area dorsal hand/forearm define extensor surface hand/forearm elbow base finger ( finger NOT include treatment area ) .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<mesh_term>Tazarotene</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>1 . Subject male nonpregnant female age 18 year . Females must postmenopausal , surgically sterile use medically acceptable form birth control , negative urine pregnancy test Baseline visit . 2 . Subject provide write verbal informed consent . 3 . Subject least four ( 4 ) AK lesion ( Grade 1 2 ) Treatment Area ( dorsal forearm/hand surface ) , least 3 lesion continuous 25 cm2 Target Area hand forearm . 4 . Subject willing comply study instruction return clinic require visit . 1 . Subject pregnant , lactating , plan become pregnant study . 2 . Subject history cutaneous photosensitization , porphyria , hypersensitivity porphyrin photodermatosis condition associate immunosuppression ( e.g . HIV , systemic malignancy , etc. ) . 3 . Subject skin pathology condition could interfere evaluation test product require use interfere topical systemic therapy . 4 . Subject condition , investigator 's opinion , would make unsafe subject participate research study . 5 . Subject currently enrol investigational drug device study . 6 . Subject receive investigational drug treat investigational device within 30 day prior initiation treatment ( baseline ) . 7 . Subject unable communicate cooperate investigator due language problem , poor mental development , impaired cerebral function . 8 . Subject may unreliable study include subject engage excessive alcohol intake drug abuse , subject unable return schedule followup visit . 9 . Subject know sensitivity one vehicle component ( ethyl alcohol , isopropyl alcohol , laureth 4 , polyethylene glycol ) . 10 . Subject know sensitivity one component Tazorac ( tazarotene , benzyl alcohol , ascorbin acid , butylate hydroxyanisole , butylate hydroxytoluene , carbomer 934P , edentate disodium , hexylene glycol , poloxamer 407 , polyethylene glycol 400 , polysorbate 40 , tromethamine ) . 11 . Subject need expose artificial tanning device excessive sunlight trial . 12 . Subject use photosensitizing drug , ( e.g . thiazide , tetracycline , fluoroquinolones , phenothiazine , sulfonamide , etc ) within timeframe photosensitization drug may still present , need use trial . 13 . Subject use follow topical preparation dorsal hands/forearms : · Keratolytics include urea ( great 5 % ) , alpha hydroxyacids [ e.g . glycolic acid , lactic acid , etc . great 5 % ] , salicylic acid ( great 2 % ) within 2 day initiation treatment . · Retinoids , include tazarotene , adapalene , tretinoin , retinol , within 4 week initiation treatment.· 5FU , cryotherapy , diclofenac , imiquimod treatment AK within 8 week initiation treatment.· Microdermabrasion , laser ablative treatment chemical peel within 8 week initiation treatment . · ALAPDT within 6 month initiation treatment . 14 . Subject use follow systemic medication : · Immunosuppressants include steroid , chemotherapy , etc . within 3 month initiation treatment· Retinoid therapy within 6 month initiation treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>ACTINIC KERATOSES</keyword>
	<keyword>HAND</keyword>
	<keyword>FOREARM</keyword>
</DOC>